Journal
INFLAMMATORY BOWEL DISEASES
Volume 19, Issue 7, Pages 1546-1555Publisher
OXFORD UNIV PRESS INC
DOI: 10.1097/MIB.0b013e318281333b
Keywords
anti-TNF-; infliximab; mechanisms of action; apoptosis; paradoxical inflammation
Categories
Funding
- Biotechnology and Biological Sciences Research Council [BBS/E/F/00044446] Funding Source: researchfish
- BBSRC [BBS/E/F/00044446] Funding Source: UKRI
Ask authors/readers for more resources
Crohn's disease (CD) is characterized by inflammation that can affect any part of the gastrointestinal tract. It is a chronic destructive condition that follows a relapsing-remitting course and can lead to disability and a poor quality of life. Lifelong pharmacotherapy with systemic immunomodulator therapies remains the cornerstone of CD management. Advances in understanding of the immunopathogenic mechanisms underlying chronic gut inflammation in CD have led to the development of effective biological therapies for patients with CD. Tumor necrosis factor (TNF-) is a potent proinflammatory cytokine that plays a pivotal role in the development of Crohn's inflammation. Therapies designed to target this cytokine have revolutionized treatment of CD since their introduction in the late 1990s, thanks to their ability to induce and maintain remission, heal mucosa, reduce hospital admissions and surgical procedures, and restore quality of life. Despite widespread use of these therapies in CD, their precise mechanism of action remains unclear, although several different mechanisms have been proposed. This review summarizes the biology of the TNF- cytokine and the development of biological therapies targeting TNF-, and updates our current understanding of mechanisms of action of the commercially available anti-TNF- therapies used in the treatment of CD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available